Actions of Novel Antipsychotic Agents on Apomorphine-Induced PPI Disruption: Influence of Combined Serotonin 5-HT1A Receptor Activation and Dopamine D2 Receptor Blockade
- 18 January 2006
- journal article
- Published by Springer Nature in Neuropsychopharmacology
- Vol. 31 (9) , 1900-1909
- https://doi.org/10.1038/sj.npp.1301015
Abstract
The dopamine D1/D2 agonist apomorphine (0.63 mg/kg) disrupted prepulse inhibition (PPI) of acoustic startle in rats, a model of sensorimotor gating deficits observed in schizophrenia. All current antipsychotics, which antagonize D2 receptors, prevent this apomorphine-induced deficit. A novel class of antipsychotics possesses, in addition to D2 antagonist property, various levels of 5-HT1A agonist activity. Considering that the latter itself produces PPI deficits, it appeared necessary to assess the potential of this novel class of antipsychotics to reverse apomorphine-PPI deficits. Potent D2 antagonists, like haloperidol (0.63–2.5 mg/kg), risperidone (0.63–10 mg/kg), and olanzapine (0.63–40 mg/kg) prevented apomorphine PPI disruption. The atypical antipsychotics, clozapine (40 mg/kg), nemonapride (0.01–2.5 mg/kg), ziprasidone (10 mg/kg), and aripiprazole (0.01 and 10 mg/kg), which all exhibit 5-HT1A agonist properties, reversed PPI deficits at some doses only, whereas the anti-dyskinetic agent sarizotan (0.16–10 mg/kg), an efficacious 5-HT1A agonist, did not. New generation antipsychotics with marked 5-HT1A agonist properties, such as SLV313 and SSR181507 (0.0025–10 mg/kg and 0.16–10 mg/kg, respectively) did not reverse these deficits whereas bifeprunox (0.04–2.5 mg/kg) did. To reveal the contribution of 5-HT1A agonist properties in the lack of effects of SLV313 and SSR181507, we pretreated rats with the 5-HT1A antagonist WAY100635 (0.63 mg/kg). Under these conditions, significant reversal of PPI deficit was observed, indicating that D2 antagonist properties of SLV313 and SSR181507 are now sufficient to overcome the disruptive effects of apomorphine. To summarize, antipsychotics possessing agonist efficacy at 5-HT1A receptors exhibit diverse profiles against apomorphine-induced PPI deficits, depending on the balance between D2 and 5-HT1A activities, suggesting that they may display distinct activity on some aspects of gating deficits in schizophrenic patients.Keywords
This publication has 63 references indexed in Scilit:
- SSR181507, a putative atypical antipsychotic with dopamine D2 antagonist and 5-HT1A agonist activities: improvement of social interaction deficits induced by phencyclidine in ratsNeuropharmacology, 2004
- Sarizotan, a serotonin 5-HT 1A receptor agonist and dopamine receptor ligand. 1. Neurochemical profileJournal Of Neural Transmission-Parkinsons Disease and Dementia Section, 2004
- SSR181507, A Dopamine D2 Receptor Antagonist and 5-HT1A Receptor Agonist. I: Neurochemical and Electrophysiological ProfileNeuropsychopharmacology, 2003
- SSR181507, A Dopamine D2 Receptor Antagonist and 5-HT1A Receptor Agonist. II: Behavioral Profile Predictive of an Atypical Antipsychotic ActivityNeuropsychopharmacology, 2003
- Serotonin 5-HT1A agonist improves motor complications in rodent and primate parkinsonian modelsNeurology, 2001
- Impact of prepulse characteristics on the detection of sensorimotor gating deficits in schizophreniaSchizophrenia Research, 2001
- The 5-HT1A receptor in schizophrenia: a promising target for novel atypical neuroleptics?Journal of Psychopharmacology, 2001
- The effects of an early stressful life event on sensorimotor gating in adult ratsSchizophrenia Research, 1998
- [3H]WAY–100635 for 5–HT1A receptor autoradiography in human brain: a comparison with [3H]8–OH–DPAT and demonstration of increased binding in the frontal cortex in schizophreniaNeurochemistry International, 1997
- Sensorimotor Gating and SchizophreniaArchives of General Psychiatry, 1990